天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Toggle Nav
Close
  • Menu
  • Setting

Glucagon (19-29), human

Catalog No.
A1019
Potent Ca2+/Mg2+-ATPase inhibitor
Grouped product items
SizePriceStock Qty
5mg
$50.00
In stock
10mg
$80.00
In stock
25mg
$110.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Glucagon(NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH) is a peptide ?hormone, secreted by the pancreas, that raises blood glucose levels. Glucagon’s effect is opposite that of insulin, which lowers blood glucose levels. Miniglucagon (Glucagon 19–29) is a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ Pathway*. Miniglucagon is a novel local regulator of the pancreatic islet physiology.? Any abnormal inhibitory tone exerted by this peptide on the β-cell results in impaired insulin secretion, as observed in type 2 diabetes. Miniglucagon is a component of the positive inotropic effect of glucagon. Some evidence has shown that glucagon processing into miniglucagon may be essential for the positive inotropic effect of glucagon on heart contraction.?

A1019_1
Ref:

1. Reece J, Campbell N (2002).?Biology. San Francisco: Benjamin Cummings.?ISBN?0-8053-6624-5.

2. Stéphane Dalle,?Ghislaine Fontés, Anne-Dominique Lajoix2, Laurence LeBrigand, René Gross,?Gérard Ribes,?Michel Dufour, Léo Barry,?Dung LeNguyen?and Dominique Bataille, Miniglucagon (Glucagon 19-29) A Novel Regulator of the Pancreatic Islet Physiology, doi:10.2337/diabetes.51.2.406Diabetes?February 2002?vol. 51?no. 2406-412

3.?Pavoine?C,?Brechler?V,?Kervan?A,?Blache Kervan,?Le-Nguyen?D,?Laurent?S, Bataille?D, Pecker?F (1991)?Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon.?Am J Physiol?260:C993–C999.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt1352.51
Cas No.64790-15-4
FormulaC61H89N15O18S
SynonymsH2N-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
Solubilityinsoluble in EtOH; insoluble in H2O; ≥135.2 mg/mL in DMSO
Chemical NameGlucagon (19-29), human
SDFDownload SDF
Canonical SMILESCC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)N
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

MIN6 cells

Reaction Conditions

0.01 ~ 1000 pM miniglucagon for 2 h incubation

Applications

Miniglucagon dose-dependently (ID50 = 1 pM) inhibited by 80 ~ 100% the insulin release triggered by glucose, glucagon, glucagon-like peptide-1-(7-36) amide (tGLP-1), or glibenclamide. Miniglucagon, at the doses active on insulin release, was able to block the increase in 45Ca2+ uptake induced by depolarizing agents (glucose or extracellular K+), glucagon, or the Ca2+ channel agonist Bay K-8644. In addition, pretreatment with pertussis toxin abolished the effects of miniglucagon on insulin release. These data suggest that miniglucagon is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein.

Note

The technical data provided above is for reference only.

References:

1. Dalle S, Smith P, Blache P, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. Journal of Biological Chemistry, 1999, 274(16): 10869-10876.

Quality Control

Chemical structure

Glucagon (19-29), human